XENE - Company ID 0001582313
The table below shows Xenon Pharmaceuticals Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $7.50M | $0.00 | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $88.51M | $77.05M | $74.98M | $61.20M | $56.97M | $49.70M |
Xenon Pharmaceuticals Inc. reported annual revenue of $7.50M for fiscal year 2025. Over the 10 fiscal years shown, annual revenue declined from $15.58M (FY 2015) to $7.50M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $23.82M |
| $19.28M |
| $19.24M |
| $19.04M |
| $16.71M |
| $19.40M |
| Operating income | -$112.33M | -$96.34M | -$94.23M | -$72.74M | -$73.68M | -$69.10M |
| Income tax | -$2.57M | $677.00K | -$626.00K | $427.00K | -$320.00K | -$333.00K |
| Net income | -$102.30M | -$90.90M | -$84.71M | -$65.05M | -$62.79M | -$57.92M |
| EPS (diluted) | -$1.17 | -$1.15 | -$1.07 | -$0.83 | -$0.81 | -$0.75 |